Literature DB >> 24715041

Is perineural invasion more accurate than other factors to predict early recurrence after pancreatoduodenectomy for pancreatic head adenocarcinoma?

Thibaut Fouquet1, Adeline Germain, Laurent Brunaud, Laurent Bresler, Ahmet Ayav.   

Abstract

BACKGROUND: Some patients operated by pancreaticoduodenectomy for resectable pancreatic head adenocarcinoma will present with a recurrence during the first year (early recurrence).
OBJECTIVE: The aim of this study was to determine prognostic factors associated with early recurrence in a large retrospective study.
METHODS: From January 1995 to November 2010, all patients operated by pancreaticoduodenectomy for pancreatic head adenocarcinoma in our institution were retrospectively included. Univariate and multivariate analyses were performed to determine factors associated with early recurrence.
RESULTS: A total of 166 patients were included; 57 patients (34%) developed early recurrence. In univariate analysis, factors associated with early recurrence were perineural invasion (p = 0.0002), preoperative bilirubin (p = 0.01), lymph node ratio (LNR) ≥0.2 (p = 0.009), and T stage (p = 0.02). In multivariate analysis, perineural invasion (odds ratio [OR] 3.31; 95% confidence interval [CI] 1.42-7.72; p = 0.005), LNR ≥0.2 (OR 2.55; 95% CI 1.17-5.52; p = 0.02), and preoperative bilirubin (OR 1.04; 95% CI 1.01-1.07; p = 0.03) were independent factors associated with early recurrence. Perineural invasion was also associated with poor overall survival (p = 0.001) and poor disease-free survival (p = 0.07).
CONCLUSION: In our study, perineural invasion (OR 3.31) is more accurate than T stage and lymph node status (OR 2.55) to predict early recurrence after pancreatoduodenectomy for pancreatic head adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24715041     DOI: 10.1007/s00268-014-2465-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  21 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

2.  Redefining resection margin status in pancreatic cancer.

Authors:  Caroline S Verbeke; Krishna V Menon
Journal:  HPB (Oxford)       Date:  2009-06       Impact factor: 3.647

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality.

Authors:  M Trede; G Schwall; H D Saeger
Journal:  Ann Surg       Date:  1990-04       Impact factor: 12.969

5.  Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy.

Authors:  Yaojun Zhang; Adam E Frampton; Charis Kyriakides; Jan J Bong; Nagy Habib; Raida Ahmad; Long R Jiao
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-04       Impact factor: 4.553

6.  Prognostic factors after surgical resection for pancreatic carcinoma.

Authors:  P Magistrelli; A Antinori; A Crucitti; A La Greca; R Masetti; R Coppola; G Nuzzo; A Picciocchi
Journal:  J Surg Oncol       Date:  2000-05       Impact factor: 3.454

7.  Histologic characteristics enhance predictive value of American Joint Committee on Cancer staging in resectable pancreas cancer.

Authors:  James Helm; Barbara A Centeno; Domenico Coppola; Marcovalerio Melis; Mark Lloyd; Jong Y Park; Dung-Tsa Chen; Mokenge P Malafa
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

8.  Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis.

Authors:  Mark B Slidell; David C Chang; John L Cameron; Christopher Wolfgang; Joseph M Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

9.  A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.

Authors:  Edward J Kim; Edgar Ben-Josef; Joseph M Herman; Tanios Bekaii-Saab; Laura A Dawson; Kent A Griffith; Isaac R Francis; Joel K Greenson; Diane M Simeone; Theodore S Lawrence; Daniel Laheru; Christopher L Wolfgang; Terence Williams; Mark Bloomston; Malcolm J Moore; Alice Wei; Mark M Zalupski
Journal:  Cancer       Date:  2013-05-29       Impact factor: 6.860

10.  The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Authors:  Hartwig Riediger; Tobias Keck; Ulrich Wellner; Axel zur Hausen; Ulrich Adam; Ulrich T Hopt; Frank Makowiec
Journal:  J Gastrointest Surg       Date:  2009-05-06       Impact factor: 3.452

View more
  8 in total

1.  Perineural Invasion Is an Independent Pathologic Indicator of Recurrence in Vulvar Squamous Cell Carcinoma.

Authors:  Emily R Holthoff; Susanne K Jeffus; Ashita Gehlot; Rebecca Stone; Stephen W Erickson; Thomas Kelly; Charles M Quick; Steven R Post
Journal:  Am J Surg Pathol       Date:  2015-08       Impact factor: 6.394

Review 2.  Re-evaluation of classical prognostic factors in resectable ductal adenocarcinoma of the pancreas.

Authors:  Daniel Åkerberg; Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Prognostic Value of Perineural Invasion in Resected Gastric Cancer Patients According to Lauren Histotype.

Authors:  Lorenzo De Franco; Daniele Marrelli; Costantino Voglino; Carla Vindigni; Francesco Ferrara; Giulio Di Mare; Livio Iudici; Mario Marini; Franco Roviello
Journal:  Pathol Oncol Res       Date:  2017-05-30       Impact factor: 3.201

Review 4.  Current Pathology Model of Pancreatic Cancer.

Authors:  Krzysztof Szymoński; Katarzyna Milian-Ciesielska; Ewelina Lipiec; Dariusz Adamek
Journal:  Cancers (Basel)       Date:  2022-05-07       Impact factor: 6.575

5.  Predictors of postoperative early recurrence of extrahepatic bile duct cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Kimihiko Ueno; Daisuke Tsugawa; Yu Hashimoto; Motofumi Tanaka; Masahiro Kido; Hirochika Toyama; Takumi Fukumoto
Journal:  Surg Today       Date:  2019-09-23       Impact factor: 2.549

6.  Stromal SLIT2 impacts on pancreatic cancer-associated neural remodeling.

Authors:  V Secq; J Leca; C Bressy; F Guillaumond; P Skrobuk; J Nigri; S Lac; M-N Lavaut; T-T Bui; A K Thakur; N Callizot; R Steinschneider; P Berthezene; N Dusetti; M Ouaissi; V Moutardier; E Calvo; C Bousquet; S Garcia; G Bidaut; S Vasseur; J L Iovanna; R Tomasini
Journal:  Cell Death Dis       Date:  2015-01-15       Impact factor: 8.469

7.  Predictive Factors of Early Recurrence in Patients with Distal Cholangiocarcinoma after Pancreaticoduodenectomy.

Authors:  Yasuhiro Ito; Yuta Abe; Tomohisa Egawa; Minoru Kitago; Osamu Itano; Yuko Kitagawa
Journal:  Gastroenterol Res Pract       Date:  2018-04-03       Impact factor: 2.260

8.  The Impact of Nerve Involvement on the Prognosis of Gastric Cancer Patients with Curative Gastrectomy: An International Multicenter Analysis.

Authors:  Kun Yang; Yu-Qing Dan; Yoon Young Choi; Zong-Guang Zhou; Woo Jin Hyung; Jian-Kun Hu; Sung Hoon Noh
Journal:  Dis Markers       Date:  2021-03-27       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.